Transfusion Medicine Reviews
Volume 21, Issue 2 , Pages 101-117 , April 2007

Modern Plasma Fractionation

  • Thierry Burnouf

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Thierry Burnouf, PhD, Human Plasma Product Services (HPPS), 18 rue Saint-Jacques, 59800 Lille, France.

References 

  1. WHO . Recommendations for the production, quality control and regulation of plasma for fractionation. http://www.who.int/bloodproducts2005;
  2. CHMP: Guideline on epidemiological data on blood transmissible infections. For inclusion in the Guideline on the Scientific data requirements for a Plasma Master File. (EMEA/CPMP/BWP/3794/03). EMEA/CPMP/BWP/125/04, January 2005. http://www.emea.eu.int: European Medicine Agency, 2005.
  3. Burgstaler E. Current instrumentation for apheresis. In:  McLeod BC,  Price TH,  Weinstein R editor. Apheresis: Principles and practice. ed 2. Bethesda, MD: AABB Press; 2003;p. 95–130
  4. Burnouf T, Kappelsberger C, Frank K, et al. Residual cell content in plasma from 3 centrifugal apheresis procedures. Transfusion. 2003;11:1522–1526
  5. Sonntag J, Emeis M, Vornwald A, et al. Complement activation during plasma production depends on the apheresis technique. Transfus Med. 1998;8:205–208
  6. Burnouf T, Eber M, Kientz D, et al. Assessment of complement activation during membrane-based plasmapheresis procedures. J Clin Apheresis. 2004;19:142–147
  7. Cardigan R, Sutherland J, Garwood M, et al. The effect of leukocyte depletion on the quality of fresh-frozen plasma. Br J Haematol. 2001;114:233–240
  8. Dodd RY. Current safety of the blood supply in the United States. Int J Hematol. 2004;80:301–305
  9. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev. 2000;14:94–110
  10. Farrugia A. Guide for the assessment of clotting factor concentrates for the treatment of hemophilia. www.wfh.org In: Montreal: World Federation of Hemophilia; 2004;p. 55
  11. Farrugia A. Plasma for fractionation: Safety and quality issues. Haemophilia. 2004;10:334–340
  12. Willkommen H, Schmidt I, Lower J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals. 1999;27:325–331
  13. Anonymous . Monograph of human plasma for fractionation 01/2005:0853 corrected. Strasbourg: European Pharmacopeia; 2005;
  14. Swärd-Nilsson A-M, Persson P-O, Johnson U, et al. Factors influencing Factor VIII activity in frozen plasma. Vox Sang. 2006;90:33–39
  15. Cohn E, Strong L, Hughes W, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–475
  16. Kistler P, Nitschmann H. Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang. 1962;7:414–424
  17. Burnouf T. Integration of chromatography with traditional plasma protein fractionation methods. Bioseparation. 1991;1:383–396
  18. Burnouf T, Radosevich M. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. J Biochem Biophys Methods. 2001;49:575–586
  19. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999;39:1160–1168
  20. Kreil TR. West Nile virus: Recent experience with the model virus approach. Dev Biol (Basel). 2004;118:101–105
  21. Yunoki M, Urayama T, Yamamoto I, et al. Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang. 2004;87:302–303
  22. Rabenau HF, Biesert L, Schmidt T, et al. SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation. Biologicals. 2005;33:95–99
  23. WHO . In: Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. 2003;p. 1–72(Geneva, www.WHO.int)
  24. CPMP . Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (revised). CPMP/BWP/CPMP/5136/03. http://www.emea.eu.int London: European Agency for the Evaluation of Medicinal Products (EMEA); 1996;
  25. Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion. 1985;25:516–522
  26. Nowak T, Niedrig M, Bernhardt D, et al. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Dev Biol Stand. 1993;81:169–176
  27. Ng PK, Dobkin MB. Pasteurization of antihemophilic factor and model virus inactivation studies. Thromb Res. 1985;39:439–447
  28. Dichtelmuller H, Rudnick D, Kloft M. Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals. 2002;30:135–142
  29. Korneyeva M, Hotta J, Lebing W, et al. Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals. 2002;30:153–162
  30. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia. 2003;9:24–37
  31. Burnouf T, Radosevich M, Goubran HA, et al. Place of nanofiltration for assuring viral safety of biologicals. Curr Nanosci. 2005;1:189–201
  32. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 2000;78:86–95
  33. WHO . WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. http://www.who.int/bloodproducts2006;
  34. Flan B, Aubin JT. Evaluation de l'efficacité des procédés de purification des proteins plasmatiques à éliminer les agents transmissibles non conventionnels. Virologie. 2005;9:S45–S56
  35. Foster PR. Removal of TSE agents from blood products. Vox Sang. 2004;87:7–10(suppl 2)
  36. Foster PR, Griffin BD, Bienek C, et al. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang. 2004;86:92–99
  37. Burdick MD, Pifat DY, Petteway SR, et al. Clearance of prions during plasma protein manufacture. Transfus Med Rev. 2006;20:57–62
  38. Tateishi J, Kitamoto T, Mohri S, et al. Scrapie removal using Planova virus removal filters. Biologicals. 2001;29:17–25
  39. Burnouf T, Burnouf-Radosevich M, Huart JJ, et al. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang. 1991;60:8–15
  40. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107:46–51
  41. Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang. 1992;62:1–11
  42. Mazurier C, Poulle M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang. 2004;86:100–104
  43. Kasper CK, Costa e Silva M. In: Registry of clotting factor concentrates. Montréal: World Federation of Hemophilia; 2005;p. 1–13
  44. Radosevich M, Goubran HA, Burnouf T. Fibrin sealant: Scientific rationale, production methods, properties, and current clinical use. Vox Sang. 1997;72:133–143
  45. Pejaudier L, Kichenin-Martin V, Boffa MC, et al. Appraisal of the protein composition of prothrombin complex concentrates of different origins. Vox Sang. 1987;52:1–9
  46. Burnouf T. Chromatography in plasma fractionation: benefits and future trends. J Chromatogr B Biomed Appl. 1995;664:3–15
  47. Burnouf T, Michalski C, Goudemand M, et al. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography. Vox Sang. 1989;57:225–232
  48. Burnouf-Radosevich M, Burnouf T. A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion. 1992;32:861–867
  49. Dickneite G, Metzner HJ, Kroez M, et al. The importance of factor XIII as a component of fibrin sealants. J Surg Res. 2002;107:186–195
  50. Tomokiyo K, Yano H, Imamura M, et al. Large-scale production and properties of human plasma-derived activated Factor VII concentrate. Vox Sang. 2003;84:54–64
  51. Burnouf T, Constans J, Clerc A, et al. Biochemical and biological properties of an alpha 1-antitrypsin concentrate. Vox Sang. 1987;52:291–297
  52. Radosevich M, Zhou FL, Huart JJ, et al. Chromatographic purification and properties of a therapeutic human protein C concentrate. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;790:199–207
  53. Kasper CK, Brooker M. Registry of clotting factor concentrates. In: ed 7. Montreal: World Federation of Hemophilia; 2006;p. 1–14
  54. Jourdain M, Carrette O, Tournoys A, et al. Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am J Respir Crit Care Med. 1997;156:1825–1833
  55. Wu R, Cui X, Lim YP, et al. Delayed administration of human inter-alpha inhibitor proteins reduces mortality in sepsis. Crit Care Med. 2004;32:1747–1752
  56. Peitsch MC, Kress A, Lerch PG, et al. A purification method for apolipoprotein A-I and A-II. Anal Biochem. 1989;178:301–305
  57. Kilpatrick DC. Isolation of human mannan binding lectin, serum amyloid P component and related factors from Cohn fraction III. Transfus Med. 1997;7:289–294
  58. Orthner CL, Ralston AH, Gee D, et al. Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate. Vox Sang. 1995;69:309–318
  59. Burnouf T, Goubran HA, Radosevich M, et al. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang. 2006;91:56–62

PII: S0887-7963(06)00094-0

doi: 10.1016/j.tmrv.2006.11.001

Transfusion Medicine Reviews
Volume 21, Issue 2 , Pages 101-117 , April 2007

Article Tools

* Image Usage & Resolution